Godavari Biorefineries, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China’s patent and trademark office for its novel anti-cancer molecule - HYDROXY-1, 4-NAPHTHALENEDIONE.
This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer.
The company’s clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, the company is deepening its focus in translational research that addresses some of the world’s most urgent health challenges.
Godavari Biorefineries is one of the manufacturers of ethanol based chemicals in India. Its diversified product portfolio comprises of bio-based chemicals, sugar, different grades of ethanol and power.
